Dopaminergic substances
The role of dopamine in behavioural arousal and the frequent occurrence of dementia in patients with Parkinson's disease provide the rationale for the use of these substances in dementia, although dopamine levels in the caudate nucleus and substantia nigra are not depressed in primary degenerative dementia (PDD)56.
L-Dopa has yielded contradictory results.6 Half of the trials reported an improvement in behaviour, but sometimes at the cost of impairment ofmemory, while the remainder found the treatment ineffective. The first studies were carried out in parkinsonian patients and showed an improvement in cognitive performance,57'58 but subsequent trials failed to confirm this effect. 59 In a crossover trial in 120 patients suffering from PDD, Schneck et al.' found that the patients responding to L-dopa showed an improvement in psychomotor function and mood, whereas patients responding to choline showed some improvement in memory functions.
A few studies have been carried out with amantadine either in elderly deteriorated patients6' or in elderly patients suffering from impairment of memory. 62 The efficacy of amantadine was evaluated, using a battery of tests, in a small number of patients who did not meet the criteria of senile dementia. Thus, despite the good results reported, no assessment can be made of the drug's effectiveness in this disease.
Nicrosini & Pasotti63 compared piribedil with Codergocrine mesylate in 30 patients suffering from 'cerebral arteriosclerosis', with favourable results and few side effects. Other trials on larger numbers of patients whose clinical status was not much better defined, concluded that piribedil is partially effective." '65 In an open trial bromocriptine was and that choline-acetyl-transferase levels are depressed83-85 prompted a number of clinical trials of the acetylcholine precursors choline and lecithin. As usual these trials ran in two phases: first a series of open or small-scale trials, some of which produced moderate improvement in memory86" while others yielded negative results.9' 94In a second phase the compounds were the subject ofcontrolled clinical trials which were nearly all negative.95" Another cholinergic precursor, deanol, was investigated in a few trials and found to have no effect on any of the symptoms of dementia.6 98
As a parallel development, physostigmine was tested because ofits indirect cholinomimetic action: apart from modest and usually transient improvement in memory,9 "'04 no lasting effect was observed on the intellectual performance and the day-to-day behaviour of patients with Alzheimer's disease. This applied whether the drug was given alone or together with lecithin.'05" 06 Furthermore, the drug has a number of practical drawbacks: it is poorly absorbed from the gut, has a short plasma half-life and, with a bellshaped dose-effect curve, it produces appreciable side effects, as the toxic blood level is close to the therapeutic one.'07
The results obtained with other cholinomimetic agents such as 4-aminopyridine, tetrahydroaminoacridine (THA) and arecoline, were hardly more convincing, in view of the small numbers of patients studied and the short periods of observation: ' In agreement with Crook" 16 it may be concluded that acetylcholine precursors are not really effective in PDD, although some minimal improvement has been observed in patients treated with a combination of lecithin and piracetam, and with physostigmine, arecoline or THA. In our view these trials of the cholinomimetics show that, although it may be possible to improve memory in normal subjects with pharmacological agents given under experimental conditions, the same drugs are relatively ineffective in patients suffering from clinically well-defined dementia. This may be due to the fact that an alteration in the neurochemical target systems is the cause both of the symptoms (here memory impairment) and of the resistance of these symptoms to treatment. Nevertheless, this particular therapeutic approach is still an interesting one, and it is likely that more effective and better tolerated drugs -cholinesterase inhibitors and direct agonists -will soon be developed and submitted to clinical testing.
Psychotropic agents: neuroleptics, minor tranquillizers, antidepressants
The use of psychotropic agents in senile dementia is based on the hypothesis that anxiety and depression, possibly engendered by the patient's awareness of the deterioration in his condition, and the agitation resulting from mental confusion are factors which contribute to the patient's loss of independence and to the intolerance he arouses in those around him. Drugs of this type have not been investigated in many trials since the 1970s.
Neuroleptics have fallen into disfavour, at least for the early stages of the disease, because in many patients they can precipitate confusion or exacerbate dementia."7 Trials have been carried out mainly with chlorpromazine, trifluoperazine, haloperidol, thioridazine, penfluridol, butyrylperazine and thiothixene."8 The positive trials reported an improvement in behaviour and agitation, whereas other studies indicated that at moderate doses neuroleptics are either without effect on behavioural disturbances or may, indeed, exacerbate the mental disturbances. Nevertheless, these drugs are useful when behavioural symptoms become intolerable for those close to the patients, and they make it possible to avoid or postpone admission to an institution.
The prevailing opinion is that, on the whole, neuroleptics should be avoided in early dementia and should be used cautiously when serious behavioural troubles, especially when associated with paranoid states, make sedative treatment necessary.5
Minor tranquillizers are widely used, although some of them may induce or exacerbate confusional states."9 In a detailed review of tranquillizer use in psychogeriatrics,5 four trials in elderly patients suffering mainly from anxiety and/or agitation suggested that diazepam had a beneficial effect on the signs of anxiety and on insomnia. However, side effects, notably drowsiness and/or confusion, were increasingly troublesome the greater the age of the patients. In other trials oxazepam gave comparable results, but had no effect on agitation.
These findings tally with general clinical experience: the minor tranquillizers are often preferred to neuroleptics for treatment of anxiety and agitation in deteriorated elderly patients.'20 However, if the patient's condition worsens and moderate doses no longer suffice, it may be preferable to switch to neuroleptics,'2' thereby avoiding high doses of minor tranquillizers which might induce hypotension, ataxia or somnolence.
Antidepressants are used with caution in senile dementia since they may induce confusion, but they are often prescribed on the grounds that depressive 'pseudodementia"22 might be responsible wholly or in part for the signs and symptoms of mental deterioration in the elderly. The earlier literature5 does not suggest that tricyclic antidepressants are particularly effective in dementia, except in frank depressive states. On the other hand, these studies also report that side effects of antidepressants in elderly patients are not excessive. A study of Gerner et al.'23 compared trazodone with imipramine in the treatment ofdepression in elderly patients and concluded that trazodone was better tolerated but that both drugs were without effect on the cognitive deficits. A controlled trial of minaprine'24 in senile dementia (PDD and MID) indicated that cognitive function improved roughly in parallel with the improvement in the symptoms of depression, the response being better in vascular dementia than in PDD. There were few side effects. Alaproclate, which inhibits 5-hydroxytryptamine reuptake, appeared promising in a pilot study,'25 but from a controlled study in 40 
